Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era

Blood

Volumn 112, Issue 7, 2008, Pages 2694-2702

  Habermann, Thomas M ^a   Wang, Sophia S ^b   Maurer, Matthew J ^a   Morton, Lindsay M ^b   Lynch, Charles F ^c   Ansell, Stephen M ^a   Hartge, Patricia ^b   Severson, Richard K ^d   Rothman, Nathaniel ^b   Davis, Scott ^e   Geyer, Susan M ^a   Cozen, Wendy ^f   Chanock, Stephen J ^b   Cerhan, James R ^a  

^a Mayo Clinic   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR2; COLONY STIMULATING FACTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 12P35; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR; INTERLEUKIN 9; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONCOGENE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; DEMOGRAPHY; GENETICS; IMMUNOLOGY; LARGE CELL LYMPHOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; ROC CURVE; SURVIVAL; TIME; UNITED STATES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DEMOGRAPHY; FEMALE; HAPLOTYPES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 53449095327     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-111658     Document Type: Article

References (50)

1. Jaffe ES, Harris N, Stein H, Vardiman J. World Health Organization Classification of Tumours. Pathology & Genetics: Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press: 2001.
2. Morton LM, Wang SS, Devesa SS, Hartge P. Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
4. Feugier P, van Hoof A, Sebban C, et al. Longterm results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de I'Adulte. J Clin Oncol. 2005;23: 4117-4126.
5. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP vs CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24: 3121-3127.
6. Gascoyne RD. Emerging prognostic factors in diffuse large B cell lymphoma. Curr Opin Oncol. 2004;16:436-441.
7. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005;23: 6351-6357.
8. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
9. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A. Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991-9996.
10. Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105: 1851-1861.
11. Hunter KW, Crawford NP. Germ line polymorphism in metastatic progression. Cancer Res. 2006;66:1251-1254.
12. Cerhan JR, Wang SS, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood. 2007;109:5439-5446.
13. Kurzrock R. Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin Cancer Res. 1997;3:2581-2584.
14. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
15. Rothman N. Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27-38.
16. Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 2006;66:9771-9780.
17. Lan Q, Zheng T Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 2006; 107:4101-4108.
18. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 1998;91:3574-3581.
19. Juszczynski P, Kalinka E, Bienvenu J, etal. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood. 2002;100:3037-3040.
20. Lech-Maranda E, Baseggio L, Bienvenu J, et al. lnterleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood. 2004;103:3529-3534.
21. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007; 110:695-708.
22. Packer BR, Yeager M, Staats B, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res. 2004;32:D528-D532.
23. Cox DR. Regression models and life tables (with discussion). J R Statist Soc B. 1972;34:187-220.
24. Freidlin B, Zheng G, Li Z, Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered. 2002;53:146-152.
25. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
26. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
27. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425-434.
28. Taylor J, Tibshirani R. A tail strength measure for assessing the overall univariate significance in a dataset. Biostatistics. 2006;7:167-181.
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57: 289-300.
30. Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006;78:464-479.
31. Heagerty PJ, LumleyT, Pepe MS. Timedependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56:337-344.
32. *Stat Database: Incidence-SEER 9 Regs Limited-Use, Nov 2007 Sub (1973-2005) , Linked To County Attributes, Total U.S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission, (www.seer.cancer.gov). Accessed on May 17, 2007.
33. Warzocha K, Salles G, Bienvenu J, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol. 1997;15:499-508.
34. Hulkkonen J, Laippala P, Hurme M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Netw. 2000;11:251-255.
35. McDowell TL, Symons JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum. 1995;38:221-228.
36. Purdue MP, Lan Q, Kricker A, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis. 2007;28:704-712.
37. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10:4895-4900.
38. Shirakawa I, Deichmann KA, Izuhara I, Mao I, Adra CN, Hopkin JM. Atopy and asthma: genetic variants of IL-4 and IL-13 signalling. Immunol Today. 2000;21:60-64.
39. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood. 2003;101:433-440.
40. Schroder AJ, Pavlidis P, Arimura A, Capece D, Rothman PB. Cutting edge: STAT6 serves as a positive and negative regulator of gene expression in IL-4-stimulated B lymphocytes. J Immunol. 2002;168:996-1000.
41. Lu X, Nechushtan H, Ding F, et al. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood. 2005;105:2924-2932.
42. Berglund M, Thunberg U, Roos G, Rosenquist R, Enblad G. The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood. 2005;105:4894-4895; author reply 4895.
43. Kube D, HuaT-D, Kloss M, et al. The interleukin-10 gene promoter polymorphism-1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun. 2007;8:164-167.
44. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, HuizingaTW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A. 1998;95:9465-9470.
45. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1-8.
46. Gibson AW, Edberg JC, Wu J, Westendorp RG, HuizingaTW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol. 2001; 166:3915-3922.
47. Blay JY, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood. 1993;82:2169-2174.
48. Stasi R, Zinzani L, Galieni P, et al. Clinical implications of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol. 1995;54:9-17.
49. Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood. 1995;85:2516-2520.
50. Fabre-Guillevin E, Tabrizi R, Coulon V, et al. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma. 2006;47:603-611.